Current Report Filing (8-k)
June 22 2017 - 3:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 21, 2017
CARA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36279
|
|
75-3175693
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
4 Stamford Plaza
107 Elm Street
Stamford,
Connecticut
|
|
06902
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (203) 406-3700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (
see
General Instruction A.2.):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒.
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒.
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
On June 21, 2017, Cara
Therapeutics, Inc. (the Company) held its Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the Companys stockholders voted on the two proposals set forth below. A more detailed description of each
proposal is set forth in the Companys Proxy Statement filed with the Securities and Exchange Commission on May 10, 2017.
Proposal 1
Election of Directors
Dr. Derek Chalmers and Mr. Martin Vogelbaum were elected to serve as directors of the Companys
Board of Directors until the 2020 Annual Meeting of Stockholders and until their successors are duly elected or until their earlier resignation or removal, by the following votes:
|
|
|
|
|
|
|
Nominee
|
|
Votes For
|
|
Votes Withheld
|
|
Broker Non-Votes
|
Dr. Derek Chalmers
|
|
9,723,635
|
|
1,280,647
|
|
13,758,180
|
Mr. Martin Vogelbaum
|
|
9,171,424
|
|
1,832,858
|
|
13,758,180
|
Proposal 2 Ratification of the Selection of Independent Registered Public Accounting Firm
The stockholders ratified the selection of Ernst & Young LLP as the Companys independent registered public accounting firm for
the year ending December 31, 2017, by the following votes:
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Votes Abstain
|
24,181,296
|
|
508,356
|
|
72,810
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
CARA THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ JOSEF SCHOELL
|
|
|
Josef Schoell
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial and Accounting Officer)
|
Date: June 22, 2017
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jul 2023 to Jul 2024